Codexis Past Earnings Performance
Past criteria checks 0/6
Codexis's earnings have been declining at an average annual rate of -39.1%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 12.6% per year.
Key information
-39.1%
Earnings growth rate
-34.6%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 12.6% |
Return on equity | -88.0% |
Net Margin | -108.7% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching
May 10Codexis: A Company Rooting Itself In A Blossoming Market
Apr 18We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Apr 09Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?
Mar 14Revenue & Expenses BreakdownBeta
How Codexis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 70 | -76 | 53 | 0 |
30 Sep 23 | 74 | -82 | 53 | 0 |
30 Jun 23 | 99 | -57 | 55 | 0 |
31 Mar 23 | 116 | -48 | 52 | 0 |
31 Dec 22 | 139 | -34 | 52 | 0 |
30 Sep 22 | 133 | -31 | 52 | 0 |
30 Jun 22 | 135 | -19 | 51 | 0 |
31 Mar 22 | 122 | -21 | 54 | 0 |
31 Dec 21 | 105 | -21 | 49 | 0 |
30 Sep 21 | 101 | -15 | 46 | -33 |
30 Jun 21 | 83 | -23 | 42 | 0 |
31 Mar 21 | 72 | -25 | 37 | 0 |
31 Dec 20 | 69 | -24 | 35 | 0 |
30 Sep 20 | 67 | -21 | 34 | 33 |
30 Jun 20 | 70 | -14 | 33 | 0 |
31 Mar 20 | 68 | -14 | 32 | 0 |
31 Dec 19 | 68 | -12 | 32 | 0 |
30 Sep 19 | 66 | -12 | 31 | 0 |
30 Jun 19 | 61 | -14 | 30 | 0 |
31 Mar 19 | 62 | -11 | 30 | 0 |
31 Dec 18 | 61 | -11 | 29 | 0 |
30 Sep 18 | 66 | -9 | 30 | 0 |
30 Jun 18 | 59 | -18 | 31 | 0 |
31 Mar 18 | 56 | -20 | 30 | 0 |
31 Dec 17 | 50 | -23 | 29 | 0 |
30 Sep 17 | 38 | -29 | 28 | 0 |
30 Jun 17 | 43 | -18 | 25 | 0 |
31 Mar 17 | 49 | -9 | 25 | 0 |
31 Dec 16 | 49 | -9 | 25 | 0 |
30 Sep 16 | 50 | -5 | 24 | 0 |
30 Jun 16 | 53 | -1 | 25 | 0 |
31 Mar 16 | 43 | -9 | 24 | 0 |
31 Dec 15 | 42 | -8 | 22 | 0 |
30 Sep 15 | 44 | -5 | 21 | 0 |
30 Jun 15 | 34 | -15 | 21 | 0 |
31 Mar 15 | 35 | -18 | 21 | 0 |
31 Dec 14 | 35 | -19 | 22 | 0 |
30 Sep 14 | 31 | -29 | 22 | 0 |
30 Jun 14 | 27 | -34 | 23 | 0 |
31 Mar 14 | 28 | -38 | 25 | 0 |
31 Dec 13 | 32 | -41 | 27 | 0 |
30 Sep 13 | 30 | -47 | 26 | 0 |
30 Jun 13 | 53 | -40 | 29 | 0 |
Quality Earnings: CDXS is currently unprofitable.
Growing Profit Margin: CDXS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CDXS is unprofitable, and losses have increased over the past 5 years at a rate of 39.1% per year.
Accelerating Growth: Unable to compare CDXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDXS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).
Return on Equity
High ROE: CDXS has a negative Return on Equity (-88.02%), as it is currently unprofitable.